Introduction The clinician's choice of treatment for gonorrhoea focuses on clinical efficacy, patient acceptability and toxicity. These criteria inevitably encompass consideration of in vitro antimicrobial sensitivities, the pharmacokinetic properties of candidate antimicrobials, anticipated compliance, cost-effectiveness, ease of administration, patient's age, pregnancy and previous adverse drug reactions. Concomitant infection with other sexually transmitted pathogens should be sought and managed appropriately.
No takes yet. Share an insight, caveat, or question.
C J Bignell (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: